Hidradenitis Suppurativa Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hidradenitis Suppurativa – Drugs In Development, 2022, provides an overview of the Hidradenitis Suppurativa (Dermatology) pipeline landscape.

Hidradenitis suppurativa is a chronic skin condition that features pea-sized to marble-sized lumps under the skin. Also known as acne inversa, these deep-seated lumps typically develop where skin rubs together such as the armpits, groin, between the buttocks and under the breasts.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hidradenitis Suppurativa – Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Hidradenitis Suppurativa (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hidradenitis Suppurativa (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Hidradenitis Suppurativa and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 19, 9, 9, 3 and 1 respectively.

Hidradenitis Suppurativa (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Hidradenitis Suppurativa (Dermatology).

– The pipeline guide reviews pipeline therapeutics for Hidradenitis Suppurativa (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Hidradenitis Suppurativa (Dermatology) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Hidradenitis Suppurativa (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Hidradenitis Suppurativa (Dermatology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Hidradenitis Suppurativa (Dermatology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Hidradenitis Suppurativa (Dermatology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies mentioned

AbbVie Inc

Acelyrin Inc

Aclaris Therapeutics Inc

Afecta Pharmaceuticals Inc

Alvotech ehf

Amgen Inc

AnaptysBio Inc

AstraZeneca Plc

Attillaps Holdings Inc

Azora Therapeutics Australia Pty Ltd

BioXpress Therapeutics SA

Boehringer Ingelheim International GmbH

ChemoCentryx Inc

CSL Ltd

Eli Lilly and Co

Ichnos Sciences Inc

Immunwork Inc

Incyte Corp

InflaRx NV

Inmagene Biopharmaceuticals Ltd

Innovation Pharmaceuticals Inc

Johnson & Johnson

Jubilant Therapeutics Inc

Kiniksa Pharmaceuticals Ltd

Kymera Therapeutics, Inc

Lytix Biopharma AS

NeuClone Pty Ltd

NovaRock Biotherapeutics Inc

Novartis AG

Pfizer Inc

Pharmapraxis

Phoenicis Therapeutics Inc

Regranion LLC

Rigel Pharmaceuticals Inc

Staidson (Beijing) Biopharmaceuticals Co Ltd

UCB SA

Union Therapeutics AS

VYNE Therapeutics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Hidradenitis Suppurativa - Overview

Hidradenitis Suppurativa - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Hidradenitis Suppurativa - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Hidradenitis Suppurativa - Companies Involved in Therapeutics Development

Hidradenitis Suppurativa - Drug Profiles

Hidradenitis Suppurativa - Dormant Projects

Hidradenitis Suppurativa - Discontinued Products

Hidradenitis Suppurativa - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Hidradenitis Suppurativa, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Companies, 2022 (Contd..1)

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Companies, 2022 (Contd..2)

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Hidradenitis Suppurativa – Pipeline by AbbVie Inc, 2022

Hidradenitis Suppurativa – Pipeline by Acelyrin Inc, 2022

Hidradenitis Suppurativa – Pipeline by Aclaris Therapeutics Inc, 2022

Hidradenitis Suppurativa – Pipeline by Afecta Pharmaceuticals Inc, 2022

Hidradenitis Suppurativa – Pipeline by Alvotech ehf, 2022

Hidradenitis Suppurativa – Pipeline by Amgen Inc, 2022

Hidradenitis Suppurativa – Pipeline by AnaptysBio Inc, 2022

Hidradenitis Suppurativa – Pipeline by AstraZeneca Plc, 2022

Hidradenitis Suppurativa – Pipeline by Attillaps Holdings Inc, 2022

Hidradenitis Suppurativa – Pipeline by Azora Therapeutics Australia Pty Ltd, 2022

Hidradenitis Suppurativa – Pipeline by BioXpress Therapeutics SA, 2022

Hidradenitis Suppurativa – Pipeline by Boehringer Ingelheim International GmbH, 2022

Hidradenitis Suppurativa – Pipeline by ChemoCentryx Inc, 2022

Hidradenitis Suppurativa – Pipeline by CSL Ltd, 2022

Hidradenitis Suppurativa – Pipeline by Eli Lilly and Co, 2022

Hidradenitis Suppurativa – Pipeline by Ichnos Sciences Inc, 2022

Hidradenitis Suppurativa – Pipeline by Immunwork Inc, 2022

Hidradenitis Suppurativa – Pipeline by Incyte Corp, 2022

Hidradenitis Suppurativa – Pipeline by InflaRx NV, 2022

Hidradenitis Suppurativa – Pipeline by Inmagene Biopharmaceuticals Ltd, 2022

Hidradenitis Suppurativa – Pipeline by Innovation Pharmaceuticals Inc, 2022

Hidradenitis Suppurativa – Pipeline by Johnson & Johnson, 2022

Hidradenitis Suppurativa – Pipeline by Jubilant Therapeutics Inc, 2022

Hidradenitis Suppurativa – Pipeline by Kiniksa Pharmaceuticals Ltd, 2022

Hidradenitis Suppurativa – Pipeline by Kymera Therapeutics, Inc, 2022

Hidradenitis Suppurativa – Pipeline by Lytix Biopharma AS, 2022

Hidradenitis Suppurativa – Pipeline by NeuClone Pty Ltd, 2022

Hidradenitis Suppurativa – Pipeline by NovaRock Biotherapeutics Inc, 2022

Hidradenitis Suppurativa – Pipeline by Novartis AG, 2022

Hidradenitis Suppurativa – Pipeline by Pfizer Inc, 2022

Hidradenitis Suppurativa – Pipeline by Pharmapraxis, 2022

Hidradenitis Suppurativa – Pipeline by Phoenicis Therapeutics Inc, 2022

Hidradenitis Suppurativa – Pipeline by Regranion LLC, 2022

Hidradenitis Suppurativa – Pipeline by Rigel Pharmaceuticals Inc, 2022

Hidradenitis Suppurativa – Pipeline by Staidson (Beijing) Biopharmaceuticals Co Ltd, 2022

Hidradenitis Suppurativa – Pipeline by UCB SA, 2022

Hidradenitis Suppurativa – Pipeline by Union Therapeutics AS, 2022

Hidradenitis Suppurativa – Pipeline by VYNE Therapeutics Inc, 2022

Hidradenitis Suppurativa – Dormant Projects, 2022

Hidradenitis Suppurativa – Discontinued Products, 2022

List of Figures

List of Figures

Number of Products under Development for Hidradenitis Suppurativa, 2022

Number of Products under Development by Companies, 2022

Number of Products by Targets, 2022

Number of Products by Stage and Targets, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2960

Saved reports